로딩 중…
StockDiggingStockDigging

Labcorp Holdings Inc.

LH· NYSE
$320.54-0.68%
2026-09-18

Financials

Valuation Metrics

Labcorp Holdings Inc.'s Market Cap is $26.28B. At end of 2025 it was $20.65B. Ranked #492 of 3,121 in US market (top 16%), #343 of 1,658 on NYSE (top 21%), #36 of 205 in Health Care Equipment & Services (top 18%) by Market Cap.

Investment Metrics(as of 2026-09-18)

MetricValue
Size
Market Cap$26.28B
Revenue$14.35B
Net Income$1.00B
Total Assets$18.53B
Net Assets$8.61B
Employees61,770
Value
P/E26.22x
P/B3.05x
PEG0.84x
P/S1.83x
EV/EBITDA15.29x
FCF Yield4.40%
Profitability
ROE11.65%
ROA5.41%
Op. Margin11.27%
Revenue Growth6.41%
Earnings Growth31.29%
Financial Health
Debt Ratio115.13%
Total Debt$6.77B
FCF$1.16B
Cash$142M
Current Ratio1.80x
Net Debt/EBITDA3.08x
Dividend
Div. Yield0.91%
Div. Growth-0.16%
Performance
1Y Return16.26%
1M Return-3.00%
From 52W High-6.22%
1Y MDD-15.22%
Trading
Volume678,995 shares
Trading Value$218M
Per Share
EPS$12.22
BPS$104.96

Company Info

CEO Mr. Adam H. Schechter
Employees 61,770
HQ Burlington, United States

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, the company offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI-enabled Test Selection, a generative AI-enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. The company was founded in 1995 and is headquartered in Burlington, North Carolina.